Daily Briefing – June 3: AI leadership pauses near record highs, oil risk returns, Marvell becomes the new AI momentum test and biotech shifts from ASCO headlines to catalyst quality

The June 3 briefing starts with a market still structurally led by AI, but no longer trading in a clean vacuum. U.S. futures paused near record highs as crude oil climbed again on renewed Middle East tension, keeping inflation and rates risk alive just as investors wait for ISM services, ADP payrolls, the Fed Beige Book and Friday’s labor report. The AI trade remains the dominant force, but the leadership map is changing: Nvidia is still the anchor, Marvell has become the newest momentum bellwether after Jensen Huang called it a potential “next trillion-dollar company,” Broadcom is the next earnings test, and Dell/HPE/NetApp keep the AI infrastructure stack in focus. In biotech, ASCO 2026 has moved from presentation hype to post-data digestion. The tape is now separating registrational evidence, early signals, randomized data, regulatory optionality and financing risk. UroGen and Teva also move onto the legal/IP watchlist after resolving JELMYTO patent litigation, while the FDA’s new draft guidance for cell and gene therapy development keeps rare-disease regulation in focus. Bottom line: June 3 is an AI-led tape under oil pressure, with biotech increasingly driven by evidence quality rather than headline excitement.

• MRVL— Marvell is the newest AI momentum test after Jensen Huang’s public endorsement pushed the stock to a record high; the market is treating custom silicon, interconnect and AI networking as a central layer of the data-center buildout.AI Momentum
• NVDA— Nvidia remains the AI anchor: new desktop and laptop chips, continued demand visibility and its influence across partners keep the stock at the center of the whole semiconductor tape.AI Leader
• AVGO— Broadcom becomes the next major AI checkpoint with earnings due after the close; investors want confirmation that custom chips, networking and hyperscaler demand remain strong beyond Nvidia.Earnings Test
• DELL / HPE— Dell and Hewlett Packard Enterprise remain key read-throughs for AI servers after strong earnings signals; the question is whether enterprise AI infrastructure can keep broadening.AI Servers
• NTAP / WDC / STX— Storage remains part of the AI stack, not a secondary story: enterprise data access, hybrid cloud, SSD demand and high-capacity storage are becoming direct AI infrastructure read-throughs.Storage
• VRT / ETN / GEV— Power, cooling and grid capacity remain strategic AI infrastructure themes because every incremental server rack creates physical demand for electrical and thermal systems.Power / Cooling
• GOOGL— Alphabet stays in the AI infrastructure discussion as investors focus on the scale of funding needed to support hyperscale AI expansion and data-center capacity.AI Capex
• URGN / TEVA— UroGen announced an agreement resolving JELMYTO patent litigation, with Teva receiving a non-exclusive license to sell a generic version beginning September 15, 2030, if approved by the FDA.Legal / IP
• URGN— UroGen remains a specialty oncology-commercial story after ZUSDURI and JELMYTO updates; the litigation resolution reduces one overhang while investors keep watching execution, reimbursement and revenue growth.Oncology
• TEVA— Teva remains a large generic/specialty pharma story where legal outcomes, branded neurology assets, generics timing and balance-sheet execution all matter for sentiment.Pharma
• IDYA— IDEAYA remains one of the higher-quality ASCO stories because darovasertib + crizotinib has a clear regulatory angle in metastatic uveal melanoma, making follow-through more about FDA path and durability than headline novelty.ASCO / Regulatory
• IMRX— Immuneering remains a pancreatic cancer validation story: the survival signal is notable, but the market still needs Phase 3 confirmation because the current setup is not the same as randomized registrational proof.ASCO / Pancreatic
• NXTC— NextCure remains an early ADC watch after SIM0505 data; the CDH6 angle is interesting, but small numbers, maturity and financing risk still matter.ASCO / ADC
• IMTX— Immatics remains one of the stronger institutional cell-therapy stories from ASCO, with PRAME TCR-T execution and the SUPRAME Phase 3 path still central to the thesis.ASCO / Cell Therapy
• ACTU— Actuate remains a pancreatic cancer biomarker-validation story; randomized Phase 2 signals help, but investors still need a clear Phase 3 strategy and prospective confirmation.ASCO / Biomarker
• BCTX— BriaCell remains high beta after ASCO: survival and biomarker signals matter, but the decisive event is still the unblinded Bria-ABC Phase 3 readout.ASCO / Breast
• REPL— Replimune remains an FDA headline-risk name after the RP1 CRL/resubmission narrative; any formal update on timing or agency posture can move sentiment quickly.FDA / Biotech
• BBIO / VERA / CAPR / CELC— The near-term FDA calendar remains important for biotech traders, with priority reviews and PDUFA dates keeping rare disease, renal, neuromuscular and oncology names in focus.PDUFA Watch

• Oil back in focus— Brent moved higher as Middle East tension returned to the foreground, reminding traders that energy prices can quickly change the inflation and rates conversation.Oil / Geo
• Futures pause— U.S. futures stalled near record highs rather than breaking down, showing that AI strength still offsets macro pressure, but the margin of safety is thinner.Market
• AI breadth test— The tape needs confirmation beyond Nvidia: Marvell, Broadcom, Dell, HPE, NetApp, Vertiv and Eaton now matter because AI is being priced as a full infrastructure cycle.AI Infra
• Rates watch— If oil and labor data push yields higher together, duration-sensitive growth, unprofitable biotech and small caps can come under pressure even while mega-cap AI holds up.Rates
• Data day— ISM services, ADP payrolls and the Fed Beige Book are the immediate macro checks before Friday’s labor report; the market wants strength without a renewed inflation scare.Jobs / ISM
• Middle East premium— The risk is not only crude price itself, but the possibility that geopolitical headlines keep inflation expectations sticky and force investors to de-risk cyclicals and small caps.Geo Risk
• ASCO digestion— Biotech is now past the easy preview stage: the tape is separating registrational data, single-arm survival signals, biomarker subgroups, early ADC data and safety lead-ins.Biotech
• FDA policy watch— The FDA’s draft guidance on using prior knowledge in cell and gene therapy development could matter for rare-disease names, especially where traditional large trials are difficult.Regulatory
• Small-cap filter— IWM and XBI remain the breadth check: if they lag while QQQ and SOXX hold up, the rally remains narrow and catalyst-dependent.Breadth
• Main risk— The tape stays constructive only if AI earnings visibility remains stronger than oil, rates and geopolitical risk; otherwise leadership can compress back into the cleanest mega-cap AI names.Tape